ARD Podcast
BMJ Group
Annals of the Rheumatic Diseases (ARD) is an international peer-reviewed journal committed to promoting the highest standards of scientific exchange and education. It covers all aspects of rheumatology, which includes the spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders. ARD publishes basic, clinical, and translational scientific research. Concise scientific communication is encouraged and peer-reviewed proceedings of international meetings are featured. ARD is the official journal of EULAR.
Catégories: Santé
Écoutez le dernier épisode:
Join our host Dr. Fabian Proft, ARD's Social Media Advisor, as he discusses the updated 2023 EULAR recommendations for imaging in large vessel vasculitis (LVV) with Professor Christian Dejaco and Dr. Milena Bond, the lead authors of the manuscript. This episode covers the latest evidence on ultrasound, MRI, CT, and FDG-PET for diagnosing and monitoring LVV. Key highlights include: Ultrasound as the first-line imaging test for giant cell arteritis. Preferred imaging modalities for Takayasu arteritis. Use of imaging for assessing vessel abnormalities and long-term monitoring. Insights into the research agenda for imaging in large vessel vasculitides. Tune in to learn how these updates aim to enhance patient care and stay informed on the latest developments in rheumatology imaging.Please subscribe to the ARD podcast on all podcast platforms, including Apple Podcast, Stitcher and Spotify. If you enjoy the show, feel free to leave us a comment or a review on the podcast iTunes page - https://podcasts.apple.com/gb/podcast/ard-podcast/id1171058059 .
Épisodes précédents
-
34 - Use of imaging in large vessel vasculitis: EULAR 2023 update Fri, 21 Jun 2024 - 0h
-
33 - Managing Systemic Lupus Erythematosus: the latest EULAR recommendations Mon, 22 Apr 2024 - 0h
-
32 - A non-pharma approach in systemic lupus erythematosus and systemic sclerosis Mon, 30 Oct 2023 - 0h
-
31 - Innate Lymphoid Cells link TGFb and fibrotic pathways in systemic sclerosis skin Mon, 07 Feb 2022 - 0h
-
30 - EULAR recommendations for the management of systemic lupus erythematosus Fri, 12 Jul 2019 - 0h
-
29 - Musculoskeletal diseases on the rise worldwide and affecting developed countries the most Mon, 03 Jun 2019 - 0h
-
28 - Three tips to get your manuscript published by ARD Wed, 29 Aug 2018 - 0h
-
27 - Early inflammatory arthritis outcomes: what changed in the new millennium? Tue, 10 Jul 2018 - 0h
-
26 - Similar performance of Humira and BI695501 biosimilar in active rheumatoid arthritis Wed, 28 Mar 2018 - 0h
-
25 - Patient and doctor discordance may reduce chances of remission in rheumatoid and psoriatic arthritis Wed, 31 Jan 2018 - 0h
-
24 - Lupus and Hughes syndrome: EULAR recommendations for women’s health and family planning Thu, 20 Apr 2017 - 0h
-
23 - Inflammatory arthritis and sicca syndrome induced by cancer treatment Tue, 06 Dec 2016 - 0h
-
22 - Johannes Bijlsma Thu, 03 Jul 2014 - 0h
-
21 - Immunogenicity of anti-SARS-CoV-2 mRNA vaccines in patients with rheumatic diseases Thu, 29 Jul 2021 - 0h
-
20 - The EULAR COVID-19 database and its insights into risk factors Thu, 18 Mar 2021 - 0h
-
19 - Predictors of disease worsening in systemic sclerosis Tue, 15 Sep 2020 - 0h
-
18 - Treating Cytokine Storm Syndrome in COVID-19 patients with glucocorticoids and tocilizumab Thu, 06 Aug 2020 - 0h
-
17 - The dose dependent effect of statins on osteoporosis Wed, 22 Apr 2020 - 0h
-
16 - A prediction score for individuals at risk to develop rheumatoid arthritis Wed, 25 Mar 2020 - 0h
-
15 - Prediction of radiographic progression using synovitis characteristics Fri, 06 Mar 2020 - 0h
-
14 - Six-week treatment with low-dose prednisolone in patients with painful hand osteoarthritis Tue, 18 Feb 2020 - 0h
-
13 - Highlights from ACR: guselkumab, ixekizumab and secukinumab in SpA Thu, 23 Jan 2020 - 0h
-
12 - TULIP 2: Efficacy and Safety of Anifrolumab in Patients Mon, 23 Dec 2019 - 0h
-
11 - TULIP 1 - highlights from the ACR meeting Tue, 10 Dec 2019 - 0h
-
10 - Capture Hi-C reveals novel drug targets in rheumatic diseases Thu, 22 Aug 2019 - 0h